| Ytd | 64.75% | |
| 1y | 142.16% |
| Open | 27.84 | Prev Close | 28.15 | Low | 27.40 | High | 28.28 | Mkt Cap | 1.54B |
| Vol | 61.47K | Avg Vol | 675.35K | EPS | -2.78 | P/E | -10.13 | Forward P/E | -7.96 |
| Beta | -0.81 | Short Ratio | 10.80 | Inst. Own | 104.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 24.02 | 200-d Avg | 19.55 | 1yr Est | 31.46 |
BCAX News
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negat
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clini
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembroliz
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for onco
Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on tr
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transc
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage b
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics NASDAQ: BCAX said it made progress during the first quarter of 2026 on the devel
Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-wee
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider s
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage b
Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report)'s stock price hit a new 52-week high durin
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage
Shares of Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report) reached a new 52-week high on We
The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bi
Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-H
Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW c
Bicara Therapeutics Inc. (BCAX) Q4 2025 Earnings Call Transcript
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the